A Study of Monthly Subcutaneous or Intravenous Mircera in Dialysis Patients With Chronic Renal Anaemia
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This open label, single arm study will assess the efficacy for long-term maintenance of
haemoglobin levels and the safety and tolerability of methoxy polyethylene glycol-epoetin
beta [Mircera] in dialysis patients with chronic renal anaemia. Patients on regular long-term
haemodialysis or peritoneal dialysis will receive monthly subcutaneous or intravenous Mircera
for 6 months. Target sample size is <200 patients.